Assessment of the Oxygen Use and Future Outcomes Associated With Oxygen Use in Patient With Fibrotic ILD

Time to Oxygen Therapy Initiation

时间窗: Up to 2099 days (from 01 October 2016 through 30 June 2022 (patient identification period)).

Time from the fibrosing Interstitial Lung Disease (ILD) diagnosis date to oxygen therapy initiation is reported. Descriptive statistics are rounded to one decimal place.

Sustained Oxygen Therapy Use Within the First 12 Months of Follow-up

时间窗: Up to month 12 of follow-up, in patient identification period from 01 October 2016 through 30 June 2022.

The number of participants with ≥ 11 claims for oxygen therapy within 12 months of initiating oxygen therapy is reported. Using claims, sustained oxygen therapy use was defined among patients with at least 12 months of follow-up after the index date (oxygen initiation date), as a binary variable for the presence of ≥11 claims for oxygen therapy in a 12-month period.

Time to Sustained Oxygen Therapy Use

时间窗: Up to 2099 days (from 01 October 2016 through 30 June 2022 (patient identification period)).

Time between the fibrosing ILD diagnosis date and the earliest date that defined the sustained oxygen therapy use is reported. Sustained oxygen therapy was defined as ≥ 11 claims for oxygen therapy within 12 months of initiating oxygen therapy.

Number of Participants With Disease Progression From Pre-index Forced Vital Capacity (FVC) Result to Index Date

时间窗: Up to 12 months prior to the index date (between 01 October 2016 through 30 June 2022 (patient identification period)).

The Number of participants with disease progression is reported instead of time to disease progression in the Outcome Measure Data Table. Disease progression was defined as a 10% relative change between the forced vital capacity (FVC) pre-index value and the index date.

Number of Participants With Disease Progression From Index Date to Follow-up Forced Vital Capacity (FVC) Result

时间窗: Up to month 12 of follow-up, in patient identification period from 01 October 2016 through 30 June 2022.

The Number of participants with disease progression is reported instead of time to disease progression in the Outcome Measure Data Table. Disease progression was defined as a 10% relative change between the index date to follow-up FVC result.

Time to All-cause Mortality

时间窗: Up to 2099 days (from 01 October 2016 through 30 June 2022 (patient identification period)).

Time to all-cause mortality is calculated as time between index date and mortality date. The oxygen therapy cohort index date was defined as the first date of a claim for oxygen therapy. The no oxygen therapy cohort index date was assigned as a date that was eligible to set an index date.